Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Red Light Holland Corp. (TRIP.CN)
Toronto, ON, CA
Based in Toronto, Ontario, Red Light Holland Corp. is primarily involved in the cultivation, production, and retail of recreational magic truffles for the Dutch market. Beyond its own cultivated offerings, the company also engages in the sourcing, distribution, and international export of various truffle varieties. Its diverse product portfolio further extends to include cannabidiol (CBD) products, cannabis seeds, headshop essentials, and a selection of cannabis-infused baked goods like muffins, cookies, and cakes. These items are marketed under the iMicrodose and Maka brands and are available to consumers through 74 brick-and-mortar SmartShops, the iMicrodose.nl website, and several other online retail platforms throughout the Netherlands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.11% | +0.00% | +0.00% | +166.67% | +60.00% | +100.00% | +33.33% | -51.52% | -87.50% | -77.14% | -77.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.1% Q4'25: +8.2% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+47.7% ★ Q4'25: -57.1% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-56.9% Q4'25: -63.6% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-83.5% Q4'25: -94.7% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-56.9% Q4'25: -89.7% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.5% Q4'25: +4.2% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.65× Q4'25: -0.11× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|---|
| Revenue |
2.33M
est: 2.50M (-7.0%)
|
3.95M
est: 5.10M (-22.6%)
|
4.75M
est: 7.10M (-33.1%)
|
4.94M
est: 4.94M (+0.0%)
|
| EBITDA |
-8.55M
est: -2.34M (-265.6%)
|
-4.32M
est: -4.77M (+9.4%)
|
-6.58M
est: -6.64M (+0.9%)
|
-3.35M
est: -4.63M (+27.5%)
|
| EBIT |
-9.08M
est: -2.42M (-275.4%)
|
-4.95M
est: -4.93M (-0.4%)
|
-7.51M
est: -6.87M (-9.4%)
|
-4.13M
est: -4.78M (+13.6%)
|
| Net Income |
-14.37M
est: -8.02M (-79.1%)
|
-5.40M
est: -4.01M (-34.6%)
|
-7.63M
est: -4.01M (-90.2%)
|
-4.04M
|
| SGA |
8.42M
est: 24.67M (-65.9%)
|
5.93M
est: 50.33M (-88.2%)
|
7.22M
est: 70.07M (-89.7%)
|
5.48M
est: 48.79M (-88.8%)
|
| EPS |
-0.04
est: -0.02 (-104.5%)
|
-0.01
est: -0.01 (-45.0%)
|
-0.02
est: -0.01 (-93.0%)
|
-0.01
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Todd Michael Shapiro | Co-Founder, Chief Executive Officer & Director | 330.0K | male |
| Benjamin Lightburn | President | 130.0K | male |
| Hans Derix | President of RLH Netherlands B.V. | 129.1K | male |
| Sarit Hashkes | Chief Technology Innovation Officer | 127.3K | female |
| Keith Li | Chief Financial Officer | 11.9K | male |
| Shimshon Posen | Corporate Secretary | — | male |
| Russell Peters | Chief Creative Officer | — | male |
| Lisa Ranken | Chief Operating Officer | — | female |
| Karim Rashid | Head of Design | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRIP.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
